748 Efficacy of Standard of Care Therapy Following Experimental Debio 025 Treatment in Patients With Chronic Hepatitis C

New Frontiers of HCV Therapy in HIV/HCV Co-infection

“…Debio 025 has been studied for the treatment of HCV in HCV treatment-naïve subjects in combination with PEG-IFN-α2a over 4 weeks and demonstrated significant HCV viral load declines [40]. After the 4-week course, SVR rates were 67% among GT-1 or GT-4-infected subjects who went on to receive 48 weeks of PEG-IFN/ribavirin after a washout period, and a few subjects who had only a 4-week course of Debio 025/PEG-IFN went on to achieve SVR suggesting that ribavirin-sparing regimens containing Debio 025 could be potentially effective [41,42]. In a short monotherapy study in HIV/ HCV-co-infected subjects specifically, the drug demonstrated potent HCV activity on 14 days of therapy and also showed that Debio 025 does exhibit mild anti-HIV viral effect with a 1 log drop in HIV viral loads [43].…”